A Phase II Clinical Trial of Fruquintinib as Third Line Treatment in Advanced Pancreatic Cancer
Status:
Not yet recruiting
Trial end date:
2024-02-01
Target enrollment:
Participant gender:
Summary
A Phase II Clinical Trial of the Safety and Efficacy of Fruquintinib in Advanced Pancreatic
Cancer Patients Who Failed Second-line Gemcitabine or 5-FU Based Chemotherapy